The National Institutes of Health has signaled that genetic testing may benefit a broader population of patients with melanoma than current practice captures, a conclusion that could reshape how dermatologists and oncology teams counsel patients and their families about hereditary risk.

The NIH's statement centers on a simple but consequential claim: more melanoma patients stand to gain from germline genetic testing than the selection criteria now in wide use would suggest. At issue is who gets tested — and just as importantly, who does not.

The referral-gap problem

In current clinical practice, genetic evaluation for melanoma typically follows a checklist. Patients are referred when they present with multiple primary melanomas, early-onset disease, a strong family history of cutaneous melanoma, or a personal or family history of pancreatic cancer or other malignancies associated with CDKN2A and other high-penetrance susceptibility genes. Those criteria have guided referrals for years.

The NIH's position implies that this checklist leaves patients behind. If testing criteria identify only the most obvious hereditary cases, patients with moderate family histories, later-onset disease, or less classic presentations may never receive an evaluation that could matter for their own surveillance and for their relatives' risk stratification.

That matters clinically for several reasons. A positive germline result changes surveillance intensity for the patient, prompts cascade testing of first-degree relatives, and can inform decisions about screening for associated cancers. For dermatologists, a known pathogenic variant converts an already high-risk patient into one who warrants more frequent total-body skin examinations and tighter follow-up intervals — a management variable that is easy to act on and often underused.

Why the calculation is shifting

Several forces have pushed testing eligibility debates forward. Sequencing costs have fallen sharply over the past decade, making the cost-per-informative-result calculation look very different than it did when the current criteria were formulated. Multigene panels now evaluate a dozen or more melanoma-associated loci in a single draw, including CDKN2A, CDK4, BAP1, POT1, ACD, TERF2IP, and TERT-promoter-related susceptibility genes, rather than the single-gene testing of earlier eras.

At the same time, data accumulating from academic kindreds and population series have complicated the picture of who carries actionable variants. A meaningful fraction of pathogenic-variant carriers do not meet the classic criteria — they lack multiple primaries, they present at older ages, or their family histories are small or uninformative because of limited family structure. Criteria built around the most striking pedigrees will systematically miss these carriers.

The NIH's framing suggests the field should weigh the benefits of broader testing against the known limitations: variants of uncertain significance, modest penetrance for some genes, and the counseling resources required to handle expanded results. Those are real trade-offs, and the analysis does not erase them. But the direction of the argument is clear — the eligibility net can reasonably be cast wider than it is today.

What it means for the clinic

For dermatology practices, the immediate practical question is when to initiate the conversation. Patients with melanoma who have any family history of the disease, any second primary, or diagnoses at ages younger than the population median are natural candidates for a genetics discussion now. A referral pathway — whether to an in-house genetics service, a partnered genetic counselor, or a telegenetics platform — determines whether that discussion leads anywhere.

Payers remain a gating factor. Coverage policies for germline melanoma testing vary, and clinicians should document family-history specifics that support medical necessity under the criteria a given plan applies.

The NIH's assessment points toward an evolving standard of care in which genetic evaluation becomes a routine consideration for a larger share of the melanoma population. As evidence on penetrance, panel yield, and downstream outcomes continues to accumulate, dermatologists should expect testing eligibility discussions to move from the genetics clinic into everyday melanoma management.